What does gain loss on priority review voucher mean?

This represents the financial gain or loss recognized from the sale or transfer of a Priority Review Voucher (PRV) granted by regulatory authorities. These vouchers are valuable assets that can be sold to other companies to expedite the FDA review process for a new drug application. It serves as a non-recurring source of capital that highlights the company's success in navigating rare disease or tropical disease regulatory pathways.

PTC Therapeutics PTCT Gain Loss On Priority Review Voucher

Gain Loss On Priority Review Voucher at other companies

Capital One FinancialCOF

$0—

Invesco Mortgage CapitalIVR

$3.5K-96.7%

UnitedHealth GroupUNH

$8M—

UnitedHealth GroupUNH

-$375M—

New York Mortgage TrustADAM

$0—

Bristol-Myers SquibbBMY

$34M-88.4%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:GainLossOnPriorityReviewVoucher.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's gain loss on priority review voucher.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's gain loss on priority review voucher?: PTC Therapeutics (PTCT) reported gain loss on priority review voucher of $24.98M in Q4 2024.
What does gain loss on priority review voucher mean?: This represents the financial gain or loss recognized from the sale or transfer of a Priority Review Voucher (PRV) granted by regulatory authorities. These vouchers are valuable assets that can be sold to other companies to expedite the FDA review process for a new drug application. It serves as a non-recurring source of capital that highlights the company's success in navigating rare disease or tropical disease regulatory pathways.